Bisphosphonate inhibits alveolar bone resorption in experimentally‐induced peri‐implantitis in dogs

Abstract

The purpose of this study was to determine the effect of bisphosphonate on alveolar bone resorption in experimentally-induced peri-implantitis in beagle dogs. Experimental peri-implantitis was induced by ligation around the abutments, 6 months after placement of a fixture. Pamidronate (0.6 mg/kg) was injected intramuscularly every 3 days into each of 5 dogs. Another 5 dogs served as the control group and were injected with saline only. Peripheral blood and urine samples were collected every week up to 12 weeks after placement of the ligature. Standard X-rays were taken every week. Urinary deoxypyridinoline (DPD) and serum osteocalcin (OC) were evaluated by ELISA as markers of alveolar bone remodeling. X-ray films were analyzed with a computer image analyzer. After 12 weeks, the bone level was measured after removal of the gingival flap. The distance between the top surface of the fixture and the fundus of the defect was significantly lower in the Pamidronate group (1.59+/-0.55 mm, mean+/-SD) than in the control group (2.41+/-0.48 mm). Bone density analyzed from the X-ray films was significantly higher in the bisphosphonate group (69.2+/-8.7%, mean+/-SD) than in the control group (50.3+/-12.8%) after 2 to 8 weeks compared with the baseline value (100%). OC and DPD levels fluctuated during the experimental period. These findings suggest that bisphosphonate inhibits the progression of alveolar bone resorption during ligature-induced peri-implantitis in dogs.

Comparison of chemically and pharmaceutically modified titanium and zirconia implant surfaces in dentistry: a study in sheep

“…The early attachment of the old bone to the implant, including the inhibition of function of osteoclasts (bisphosphonates) can hamper resorption and lead to a better anchorage at the very early stage of bone healing 20 . The reduction of micromotion at a very early stage after implantation is therefore considered responsible for good osseointegration of bisphosphonate-coated implants, since initially mainly bone formation occurs.…”

Dietary Supplementation of Omega‐3 Fatty Acid and Circulating Levels of Interleukin‐1β, Osteocalcin, and C‐Reactive Protein in Rats

“…Osteocalcin (OC) is a calcium‐binding protein of bone and the most abundant non‐collagenous protein of the mineralized tissue 7 . The serum level of OC is considered a marker of bone formation 8‐10 . Increased serum concentrations of OC have been proposed to indicate an increase in bone turnover 3 .…”

Boosting effect of bisphosphonates on osteoconductive materials: a histologic in vivo evaluation

“…Long‐term prescription of bisphosphonates has been widely reported to be useful in the treatment of bone‐related pathologic conditions, such as osteogenesis imperfecta (2–4), osteoporosis (5,6), spondiloarthropathy (7), bone loss after allogenic stem cell transplantation (8), bone fracture in pediatric patients on chronic steroid therapy (9), bone metastasis or pain caused by it (10,11), calcification in elderly cancerous patients (breast and prostate carcinoma and multiple myeloma) (12), acute vitamin D intoxication (13) and Paget disease (1). Bisphosphonates have also been used to help improve the osseointegration of implants (14–16) or to improve alveolar bone resorption in peri‐implantitis (17), although these applications have been questioned by others (18).…”